Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences
03 Agosto 2022 - 5:15PM
Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage
biopharmaceutical company pioneering the development of
exosome-based therapeutics as a new class of medicines, today
announced that management will be participating in two upcoming
investor conferences.
On Monday, August 9, Codiak management will be
taking part in the BTIG Biotechnology Conference 2022, with a
fireside chat for attendees and the Company will be hosting
one-on-one meetings virtually.
On Tuesday, August 10, at the Wedbush PacGrow
Healthcare Conference 2022, Codiak’s Chief Executive Officer,
Douglas E. Williams, Ph.D., will participate in a panel discussion
entitled “For Your IOnly – Progress, Challenges in
Immuno-Oncology,” from 2:20 - 3:20 pm ET and the Company will also
be hosting one-on-one meetings virtually. A webcast of the panel
will be available on the Investors & Media section of the
Codiak website at www.codiakbio.com. The archived replay will be
available for approximately 30 days following the event.
About Codiak BioSciences Codiak is
a clinical-stage biopharmaceutical company pioneering the
development of exosome-based therapeutics, a new class of medicines
with the potential to transform the treatment of a wide spectrum of
diseases with high unmet medical need. By leveraging the biology of
exosomes as natural intercellular transfer mechanisms, Codiak has
developed its proprietary engEx® Platform to expand upon the innate
properties of exosomes to design, engineer and manufacture novel
exosome therapeutic candidates. Codiak has utilized its engEx
Platform to generate a deep pipeline of engineered exosomes aimed
at treating a broad range of disease areas, spanning oncology,
neuro-oncology, infectious disease and rare disease. For more
information, please visit www.codiakbio.com.
Investor Contact:Christopher
TaylorVP, Investor Relations and Corporate Communications T:
617-949-4220E: investor@codiakbio.com
Media Contact:Cory TrombleeScient
PRmedia@codiakbio.com
Codiak BioSciences (NASDAQ:CDAK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Codiak BioSciences (NASDAQ:CDAK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Codiak BioSciences Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de